Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is widely used as a first-line procedure for the diagnosis of pancreatic solid tumors. However, EUS-FNA is known to be associated with some serious adverse events. The rate of early adverse events, including acute pancreatitis, bleeding, infection, and duodenal perforation, is reported to be 0.98%-3.4%. [1][2][3][4][5] Recently, the incidence rate of needle tract seeding (NTS), one of the late adverse events, after EUS-FNA, is reported to be 0.33% for all primary pancreatic tumors. 6 We experienced a case involving a gastric tumor that seemed to be derived from NTS in a patient who underwent distal pancreatectomy after being diagnosed with pancreatic ductal adenocarcinoma (PDAC) based on EUS-FNA. In this case, the samples collected in a single session of EUS-FNA were sufficient to make a diagnosis. We report the details of this case and related cases described in the relevant literature.